Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1081-1090 of 3427 for cancer

Edit search filters
  1. A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination with Crizotinib

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

    Scottsdale/Phoenix, AZ

  3. Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Study to Clinically Test the Use of a Prostate Cancer Knowledge Questionnaire

    Rochester, MN

  5. Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

    Rochester, MN

  6. FT576 in Subjects With Multiple Myeloma

    Jacksonville, FL

  7. A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

    Jacksonville, FL, Rochester, MN

  9. STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

    Scottsdale/Phoenix, AZ

  10. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma

    Rochester, MN

.

Mayo Clinic Footer